Organisation paid for research Program year 2025 Source: CMS Open Payments

Alturas Analytics Inc

Neither a doctor nor a teaching hospital

Research payments

$411,567

11 payments

Through program year 2025, Alturas Analytics Inc is reported as receiving $411,567 in research payments, across 11 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$3,736	1
2024	Research	$176,720	3
2023	Research	$105,445	4
2022	Research	$125,666	3

Breakdown

Who paid Research payments · program years 2022–2025

E.R. Squibb & Sons, L.L.C. $411,567 11 payments

Studies the money was for Research payments · program years 2022–2025

Relative BA (open capsule, NG tube) - An Open-label, Randomized, Single-dose, Three-way Crossover Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered via Nasogastric Tube Compared to 5 mg Mavacamten Intact Capsule i $155,268 1 payment
Activated Charcoal Study $118,840 2 payments
Relative BA - A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Previous MyoKardia Formulation of Danicamtiv and to Assess the Effe $84,664 1 payment
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants $21,252 1 payment
DDI CYP3A4 Inhibition - An Open-label, 3-Arm, Parallel Design Pharmacokinetic Interaction Study Between MYK-224 and Cytochrome P450 3A4 Inhibitors Itraconazole and Verapamil in Healthy Participants $17,278 2 payments
DDI Study CYP3A4/p-gp (victim) Inhibitor - An Open-label, Randomized, 2-Period Crossover Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose Pharmacokinetics of Danicamtiv in Healthy Participants $10,329 2 payments
An Open-label, Randomized, Single-dose, Three-way Crossover Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered via Nasogastric Tube Compared to 5 mg Mavacamten Intact Capsule in Healthy Participants $3,736 1 payment
A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants $200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.